Participation in HIV vaccine trials: Listening to participant & community concerns

Indian Journal of Medical Research

Volumn 124, Issue DEC., 2006, Pages 608-610

  Mills, Edward J ^a,b   Jha, Prabhat ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDOM; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH EDUCATION; HEALTH PROMOTION; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INDIA; INFECTION RISK; NOTE; PANDEMIC; PATIENT PARTICIPATION; PREVALENCE; PREVENTIVE HEALTH SERVICE; RESEARCH SUBJECT; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY; PSYCHOLOGICAL ASPECT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; CLINICAL TRIALS; HUMANS;

EID: 34247113692     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Note

References (16)

1. UNAIDS. Report on the global AIDS epidemic. http://www.unaids.org/en/ HIV_data/2006GlobalReport/default.asp (Accessed Oct 31, 2006). 2006.
2. Menon-Johansson AS. Good governance and good health: The role of societal structures in the human immunodeficiency virus pandemic. BMC Int Health Hum Rights 2005; 5: 4.
3. Jha P, Nagelkerke JD, Ngugi EN, Prasada Rao JV, Willbond B, Moses S, et al. Public health. Reducing HIV transmission in developing countries. Science 2001; 292: 224-5.
4. Mills E, Siegfried N. Cautious optimism for new HIV/AIDS prevention strategies. Lancet 2006; 368: 1236.
5. Suhadev M, Nyamathi AM, Swaminathan S, Venkatesan P, Sakthivel R, Shenbagavalli, et al. A pilot study on willingness to participate in future preventive HIV vaccine trials. Indian J Med Res 2006; 124: 631-40.
6. Mills E, Cooper C, Guyatt G, Gilchrist A, Rachlis B, Sulway C, et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 2004; 18: 2235-42.
7. Mills E, Nixon S, Singh S, Dolma S, Nayyar A, Kapoor S. Enrolling women into HIV preventive vaccine trials: an ethical imperative but a logistical challenge. PLoS Med 2006; 3: e94.
8. Kumar R, Jha P, Arora P, Mony P, Bhatia P, Millson P, et al. Trends in HIV-1 in young adults in south India from 2000 to 2004: a prevalence study. Lancet 2006; 367: 1164-72.
9. World Medical Association. Declaration of Helsinki, Article 5. http://www.wma.net/e/policy/b3.htm. 2000.
10. Jefferson T. Influenza vaccination: policy versus evidence. BMJ 2006; 333: 912-5.
11. IAVI. Ongoing trials of preventive AIDS vaccines. http://www.iavireport.org/specials/ OngoingTrialsofPreventiveHIVVaccines.pdf. Accessed November 2, 2006.
12. Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004; 303: 316.
13. Watanabe ME. Skeptical scientists skewer VaxGen statistics. Nat Med 2003; 9: 376.
14. VaxGen vaccine trial fails the test but may offer insights. AIDS Alert 2003; 18: 41, 43-5.
15. Basu I, Jana S, Rotheram-Borus MJ, Swendeman D, Lee SJ, Newman P, et al. HIV prevention among sex workers in India. J Acquir Immune Defic Syndr 2004; 36: 845-52.
16. Rao Seshadri S, Subramaniyam P, Jha P. The Potential Demand for and Strategic Use of an HIV-1 Vaccine in Southern India. World Bank Policy Research Working Paper No. 3066. Available at SSRN: http://ssrn.com/ abstract=636428. World Bank Policy Research Working Paper No. 3066; 2003.